Vascular Biogenics

^{Priced, Nasdaq: VBLT}

Developing gene therapies for cancer and small molecules for inflammation.

Industry: Health Care

First Day Return: -2.5%

VBLT

Developing gene therapies for cancer and small molecules for inflammation.

IPO News for Vascular Biogenics

US IPO Pricing Recap: 11 IPOs trade poorly but investors can't get enough American Addiction 10/03/14
Vascular Biogenics prices previously canceled IPO at $6 10/02/14
US IPO Pricing Recap: 15 IPOs in the most active week since 2007; 66% ended at or below IPO price 08/01/14

IPO Data
IPO Date	09/30/2014
Offer Price	IPO Intelligence Only
Price Range	IPO Intelligence Only
Offer Shares (mm)	IPO Intelligence Only
Deal Size ($mm)	$40
Lock-Up Date	IPO Intelligence Only
Street Research	IPO Intelligence Only

Underwriters
IPO Intelligence Only

Company Data
Website www.vblrx.com
Headquarters	Or Yehuda, Israel
Founded	2000
Employees at IPO	32

IPO News for Vascular Biogenics

Vascular Biogenics (VBLT) Performance